(9CI)-2-氟喹唑啉 | 56595-08-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: (9CI)-2-氟喹唑啉
• 英文名称: Quinazoline, 2-fluoro-
• 英文别名: 2-fluoroquinazoline
• CAS: 56595-08-5
• 化学式: C₈H₅FN₂
• 分子量: 148.14
• InChiKey: CJGKNWNOOUZIDB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• HETEROBICYCLIC COMPOUNDS
  申请人：Amgen Inc.

  公开号：US20130225552A1

  公开（公告）日：2013-08-29

  Heterobicyclic compounds of Formula (I): or a pharmaceutically-acceptable salt, tautomer, or stereoisomer thereof, as defined in the specification, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, Huntington's Disease, and the like.

  Formula (I)的杂环化合物： 或其药用可接受的盐、互变异构体或立体异构体，如规范中所定义，并含有它们的组合物，以及制备这种化合物的方法。本文还提供了通过抑制PDE10来治疗由此可治疗的疾病或疾病的方法，如肥胖症、非胰岛素依赖型糖尿病、精神分裂症、躁郁症、强迫症、亨廷顿病等。
• [EN] CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF THE CHEMOKINE CCR2 RECEPTOR<br/>[FR] COMPOSÉS DE CARBOXYAMIDE ET LEUR UTILISATION COMME ANTAGONISTES DU RÉCEPTEUR CCR2DE LA CHIMIOKINE
  申请人：EPIX DELAWARE INC

  公开号：WO2009076404A1

  公开（公告）日：2009-06-18

  Chemokine receptor antagonists, in particular, compounds of Formula (I) that act as antagonists of the chemokine CCR2 receptor, including pharmaceutical compositions and uses thereof to treat or prevent diseases associated with monocyte accumulation, lymphocyte accumulation or leukocyte accumulation are described; wherein (B/A) is an optionally substituted fused aromatic or partially aromatic bicyclic ring containing at least one nitrogen atom.

  描述了特定的化学物质，即作为趋化因子CCR2受体拮抗剂的Formula (I)化合物，包括其药用组合物和用途，用于治疗或预防与单核细胞、淋巴细胞或白细胞聚积相关的疾病；其中(B/A)是一个可选择地取代的融合芳香或部分芳香的双环环，其中至少含有一个氮原子。
• [EN] QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS<br/>[FR] DÉRIVÉS DE LA QUINAZOLINE, COMPOSITIONS CORRESPONDANTES ET LEUR UTILISATION EN TANT QU'AGENTS PHARMACEUTIQUES
  申请人：SHANGHAI FOCHON PHARMACEUTICAL CO LTD

  公开号：WO2015007219A1

  公开（公告）日：2015-01-22

  Disclosed herein are protein kinase inhibitors, more particularly novel quinazoline derivatives and pharmaceutical compositions thereof,and method of use thereof.

  本文披露了蛋白激酶抑制剂，更具体地说是新颖的喹唑啉衍生物及其药物组合物，以及其使用方法。
• [EN] QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS<br/>[FR] DERIVES DE QUINAZOLINE UTILISES COMME AGENTS ANTI-TUMEUR
  申请人：ASTRAZENECA AB

  公开号：WO2005026152A1

  公开（公告）日：2005-03-24

  A quinazoline derivative of the formula (I): (A chemical formula should be inserted here - please see paper copy enclosed) Formula I wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm blooded animal such as man.

  一种喹唑啉衍生物的化学式（I）：（请参阅附上的纸质副本以获取化学式）化学式 I，其中取代基如文本中定义的那样，用于生产抗增殖作用，该作用通过在温血动物（如人）中部分或完全抑制erbB2受体酪氨酸激酶而产生。
• Carboxamide Compounds and Their Use
  申请人：Ben-Zeev Efrat

  公开号：US20100324035A1

  公开（公告）日：2010-12-23

  Chemokine receptor antagonists, in particular, compounds of Formula (I-A) that act as antagonists of the chemokine CCR2 receptor, including pharmaceutical compositions and uses thereof to treat or prevent diseases associated with monocyte accumulation, lymphocyte accumulation or leukocyte accumulation are described herein.

  化学因子受体拮抗剂，特别是化合物式(I-A)的拮抗剂，作为化学因子CCR2受体的拮抗剂，包括其药物组合物和用途，用于治疗或预防与单核细胞聚集、淋巴细胞聚集或白细胞聚集相关的疾病。